Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa -unveiling in vitro and in vivo strategies
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkaf495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Jiaju Zhuo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of PLA General Hospital, Beijing 10083, China. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Pseudomonas aeruginosa, Pseudomonas Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, New Medicine Clinical Research Fund.
Abstract (Originalsprache)
Background
Ceftazidime/avibactam (CZA) is recognized as an efficacious treatment modality against multidrug-resistant Pseudomonas aeruginosa. Nevertheless, it encounters the challenge of escalating antimicrobial resistance. Employing combination regimens involving ceftazidime/avibactam may confer advantages.
Methods
Checkerboard titration, time-kill assays, and an in vitro pharmacodynamic model were employed to investigate the effectiveness of ceftazidime/avibactam alone and in combination in vitro. Additionally, an intraperitoneal infection mouse model was established to assess the efficacy of combination therapy in vivo.
Results
In the in vitro pharmacodynamic model, administration of ceftazidime/avibactam plus polymyxin B resulted in a significant reduction in colony-forming units of all four strains, whereas ceftazidime/avibactam plus aztreonam only reduced the colonies of three strains. Significant or trending declines in mortality and tissue colony counts of infected mice were observed in groups treated with ceftazidime/avibactam plus polymyxin B. Conversely, ceftazidime/avibactam combined with aztreonam only reduced mortality and tissue colonies in MBL-positive P.aeruginosa-infected mice.
Conclusion
Combining ceftazidime/avibactam with polymyxin B might represent a potentially effective option against MDR-P.aeruginosa. Although the synergistic effect in vitro might not be readily apparent due to the potent bactericidal effect of aztreonam alone, the combination of ceftazidime/avibactam and aztreonam demonstrated promising synergistic effects on MBL-positive P.aeruginosa strains in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of PLA General Hospital, Beijing 10083, China.
- Department of Pharmacy, The Third People's Hospital of Chengdu, Chengdu 610031, China.
ORCID-Profile: Yun Cai
Förderung
- National Natural Science Foundation of China
- New Medicine Clinical Research Fund
Zitieren
APA
Zhuo, J., Xu, J., Chi, Y., Zhang, N., Fu, G., Chen, Z., Liang, B., & Cai, Y. (2026). Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa -unveiling in vitro and in vivo strategies. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf495
Vancouver
Zhuo J, Xu J, Chi Y, Zhang N, Fu G, Chen Z, et al. Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa -unveiling in vitro and in vivo strategies. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf495
BibTeX
@article{Zhuo2026,
author = {Zhuo, Jiaju and Xu, Juan and Chi, Yulong and Zhang, Na and Fu, Guanshuang and Chen, Zehua and Liang, Beibei and Cai, Yun},
title = {Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa -unveiling in vitro and in vivo strategies},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkaf495}
}
EUVIMED